Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis

Both abrocitinib and dupilumab effectively improve skin barrier function in atopic dermatitis, with distinct molecular impacts unveiled through tape-strip proteomics analysis.

This dataset contains supplemental methods, 6 supplemental figures, and 5 supplemental tables.

Mendeley supplemental figure 1. Flow diagram of subject assignments and intervention adherence
Mendeley supplemental figure 2. Representative clinical images of AD patients before and after treatment
Mendeley supplemental figure 3. Comparison of laboratory test results before and after treatment with dupilumab or abrocitinib
Mendeley supplemental figure 4. Correlation between clinical symptoms and skin barrier function during treatment
Mendeley supplemental figure 5. Distinct Gene Ontology terms and potential biomarkers in AD skin
Mendeley supplemental figure 6. Different therapies induce unique dynamic patterns of skin proteomics in AD

Mendeley supplemental table 1. Baseline details of demographics and skin barrier parameters in enrolled individuals
Mendeley supplemental table 2. Comparison of demographics and baseline clinical features within subgroups
Mendeley supplemental table 3. Differentially expressed proteins between AD lesional skin at baseline and healthy skin
Mendeley supplemental table 4. Differentially expressed proteins between AD non-lesional skin at baseline and healthy skin
Mendeley supplemental table 5. Differentially expressed proteins between lesional skin and non-lesional skin of AD at baseline